Generic Name for INVEGA
Paliperidone 1.5mg, 3mg, 6mg, 9mg; ext-rel tabs.
Legal Classification:
Rx
Pharmacological Class for INVEGA
Benzisoxazole.
Manufacturer of INVEGA
Janssen Pharmaceuticals, Inc.
|
Indications for INVEGA
Acute and maintenance treatment of schizophrenia in adults. Acute treatment of schizoaffective disorder in adults, as monotherapy or as an adjunct to mood stabilizer and/or antidepressants. Treatment of schizophrenia in adolescents 12–17yrs of age.
Adult dose for INVEGA
Swallow whole. ≥18yrs: 6mg once daily in AM; may increase in increments of 3mg/day at intervals of >4 days (for schizoaffective disorder) or >5 days (for schizophrenia) if needed. Usual range: 3–12mg/day. Max 12mg/day. Maintenance: use lowest effective dose. Renal impairment: CrCl ≥50–<80mL/min: max 6mg/day; CrCl 10–<50mL/min: max 3mg/day.
Children's dosing for INVEGA
Schizoaffective disorder: <18yrs: not recommended. Schizophrenia: <12yrs: not recommended. 12–17yrs: (<51kg): initially 3mg once daily in AM; usual range: 3–6mg/day; max 6mg/day; (≥51kg): initially 3mg once daily in AM; usual range: 3–12mg/day; max 12mg/day. Both: may increase in increments of 3mg/day at intervals of >5 days if needed.
Warnings/Precautions for INVEGA
Elderly (not for dementia-related psychosis): increased risk of death. Avoid in congenital long QT syndrome, cardiac arrhythmias. Discontinue if neuroleptic malignant syndrome (NMS) occurs; consider discontinuing if tardive dyskinesia occurs. Diabetes risk factors (obtain baseline fasting blood sugar). Cardio- or cerebrovascular disease; risks may be increased due to metabolic changes (eg, hyperglycemia, dyslipidemia, weight gain); monitor. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Orthostatic hypotension. Parkinson's disease. Dementia with Lewy bodies. History of seizures. Patients at risk for aspiration pneumonia. Renal insufficiency. Severe hepatic impairment. Exposure to extreme temperatures. May have antiemetic effect. Suicidal patients. Tabs: Pre-existing severe GI narrowing: not recommended. Reevaluate periodically. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions for INVEGA
Avoid alcohol, drugs that prolong QT interval (eg, Class 1A and Class III antiarrhythmics, chlorpromazine, thioridazine, gatifloxacin, moxifloxacin). Caution with other CNS drugs, drugs that may cause orthostatic hypotension. May be antagonized by carbamazepine; adjust dose. May antagonize levodopa, other dopamine agonists. May be potentiated by divalproex sodium; consider dose reduction.
Adverse Reactions for INVEGA
Extrapyramidal symptoms, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight gain, tachycardia, dyspepsia, constipation, nasopharyngitis; may cause NMS, tardive dyskinesia, QT prolongation, hyperglycemia, dyslipidemia, orthostatic hypotension, syncope, hyperprolactinemia, priapism.
How is INVEGA supplied?
Tabs—30